Visual Function Changes After Intraocular Pressure Reduction
Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma
Intervention: timolol maleate 0,5% (Drug); brimonidine tartrate 0,2% (Drug); travoprost 0,004% (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Sao Paulo Official(s) and/or principal investigator(s): Tiago Prata, MD, Principal Investigator, Affiliation: Federal University of Sao Paulo Luiz A Melo Jr, MD, Principal Investigator, Affiliation: Federal University of Sao Paulo
Summary
During the glaucomatous disease process, subpopulations of cells may be dead, damaged or
healthy. Visual function changes could be observed due to a recovering of the suffering
ganglion cells after the intraocular pressure reduction. This study aims at evaluating the
correlation between intraocular pressure reduction and visual function changes in glaucoma
patients after using antiglaucoma medications.
Clinical Details
Official title: Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Primary outcome: intraocular pressurecontrast sensitivity visual quality perception
Secondary outcome: Mean deviation of the visual field (MD)Pattern Standard Deviation of the visual field (PSD) visual acuity
Detailed description:
Primary open angle glaucoma patients without use of antiglaucoma medications will be
enrolled in this study. After inclusion, the patients will randomly receive one of three
antiglaucoma medications (timolol maleate 0,5%, brimonidine tartrate 0,2% or travoprost
0,004%) in one randomly selected eye.
The patients will be evaluated with Goldmann applanation tonometry, visual acuity test,
contrast sensitivity test, visual quality perception test (visual analogue scale) and
standard automated perimetry before and after 4 weeks of glaucoma treatment onset.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Primary open angle glaucoma
- Intraocular pressure greater than 21 mmHg
Exclusion Criteria:
- Best corrected visual acuity (BCVA) worse than 20/80
- Significant media opacity
- History of steroid use
Locations and Contacts
Additional Information
Starting date: September 2005
Last updated: February 16, 2007
|